Abstract #2647

The study of vascular disrupting agent A64 combined with bevacizumab in the treatment of NSCLC using Multiple b-value DWI

Chang-Zheng Shi¹, Dong Zhang², Liang-Ping LUO³, and Yong Zhang⁴

¹Jinan University, Guangzhou, China, People's Republic of, ²guangzhou, China, People's Republic of, ³Guangzhou, China, People's Republic of, ⁴GE Healthcare MR Research China, Beijing, Beijing, China, People's Republic of

Studies showed that vascular disrupting agents and angiogenesis inhibitors had a synergistic effect for the treatment of cancer. Few previous reports used MRI to assess the combination of anti-angiogenesis drugs in non-small cell lung cancer(NSCLC). MR multi-b value diffusion-weighted imaging can be used to monitor the treatment of tumor by anti-angiogenesis drugs. In our study , the nude mice xenograft model was used to evaluate the role of vascular disrupting agents combing angiogenesis inhibitor in NSCLC by multiple b-value diffusion weighted imaging (DWI).

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.